bioAffinity Technologies (NASDAQ:BIAF) Releases Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) posted its quarterly earnings results on Friday. The company reported ($2.70) earnings per share (EPS) for the quarter, Zacks reports. bioAffinity Technologies had a negative net margin of 152.16% and a negative return on equity of 845.68%. The company had revenue of $1.45 million for the quarter.

bioAffinity Technologies Stock Performance

Shares of BIAF traded down $0.04 during mid-day trading on Friday, reaching $1.84. 121,912 shares of the company’s stock traded hands, compared to its average volume of 215,494. The business’s 50-day moving average price is $3.69 and its 200-day moving average price is $6.89. The company has a debt-to-equity ratio of 0.27, a quick ratio of 0.63 and a current ratio of 0.64. The stock has a market capitalization of $6.68 million, a P/E ratio of -0.09 and a beta of 2.31. bioAffinity Technologies has a 12 month low of $1.76 and a 12 month high of $46.53.

Analyst Ratings Changes

A number of equities research analysts have issued reports on BIAF shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of bioAffinity Technologies in a research report on Wednesday, October 8th. Wall Street Zen cut shares of bioAffinity Technologies to a “strong sell” rating in a research report on Saturday, September 20th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Reduce”.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.